Artiva Biotherapeutics, Inc. 4

Director Laura Stoppel received an option award for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at a $10.42 exercise price.

On September 10, 2026, director Laura Stoppel received a stock option award from Artiva Biotherapeutics, Inc. covering 16,250 shares of common stock at an exercise price of $10.42 per share, with the option vesting in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting and expiring on September 9, 2036. The option is held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III, and a separately managed account under an arrangement with RA Capital Management, L.P., and Ms. Stoppel is required to turn over any net proceeds upon exercise, effectively disclaiming beneficial ownership of both the option and the underlying shares. Based on the exercise price, the notional value of the option grant is approximately $169,325, and following this award she is reported as directly holding 16,250 derivative securities tied to the company’s common stock.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-390558

Alert Tier

5